DPP4 and Recurrent upper respiratory tract infections: Spontaneous reporting of infections are two times higher in patients using DPP4 inhibitors compared to metformin, with reports of upper respiratory tract infections at 12 times higher13; however, there are significant limitations with spontaneous reporting and, due to underreporting of events, population-based incidence rates cannot be measured16.